Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1821-1840 of 3,900 trials

Rectal Cancer Surgery: SGM-101 Imaging Study

We are testing a new imaging agent, SGM-101, to see if it helps surgeons better detect rectal cancer during surgery. This study is for patients with locally advanced or recurrent rectal cancer who are undergoing curative surgery.

Rectal Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Rectal Polyps: SGM-101 Fluorescent Tracer Study

We are investigating a new imaging technique using SGM-101 to help identify cancerous and non-cancerous tissues in patients with rectal polyps. This study aims to improve how doctors detect early-stage rectal cancer.

Early Rectal Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Locally Advanced Rectal Cancer: Dostarlimab and Radiotherapy

We are studying a new treatment combining dostarlimab and short-course radiotherapy for patients with specific types of rectal cancer. The goal is to see if this approach helps improve treatment success and quality of life.

Locally Advanced Rectal Cancer with Genetic Deficiencies>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Metastatic Non-Small-Cell Lung Cancer: LN-145 Treatment Study

We are investigating whether LN-145, a type of immune cell therapy, is safe and effective for patients with metastatic non-small-cell lung cancer. The study will assess how well it works in shrinking tumors and improving patient outcomes.

Metastatic Non-Small-Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Knee Surgery Pain Relief: Oral vs. IV Medications

We are comparing the effectiveness of oral pain relief to intravenous options for patients after knee arthroscopy. This study aims to see which method better manages pain and affects recovery.

Postoperative Pain Relief1-2 yearsMonitoring phase (IV)Standard MedicinesOrthopedics and TraumatologyOtolaryngology

Hyperbaric Oxygen Therapy for Sudden Hearing Loss

We are studying whether adding hyperbaric oxygen treatment to standard care improves hearing in people with sudden sensorineural hearing loss. The trial will also look at quality of life and safety of this treatment approach.

Sudden Hearing Loss3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOtolaryngology

Ulcerative Colitis: CICR-NAM Treatment Study

We are testing a new oral medication for people with mild to moderately active ulcerative colitis. The goal is to see if it helps improve symptoms and overall gut health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterology

CART19 Cells for Blood Cancers

We are studying the effects of CART19 cells in patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. This research aims to explore new treatment possibilities for these challenging conditions.

Recurrent Acute Lymphoblastic Leukaemia>2 yearsSafety phase (I)HematologyOncology

Vitamin D3 Doses in Critically Ill Patients on Kidney Support

We are comparing two doses of vitamin D3 to see how they affect vitamin levels and health outcomes in ICU patients receiving kidney support. This study may help improve treatment for those with severe vitamin D deficiency.

Vitamin D DeficiencyMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyNephrology

IL12-L19L19 Treatment: Safety and Early Efficacy Study

We are investigating the safety and early signs of effectiveness of the IL12-L19L19 treatment. This study is for individuals who may benefit from new therapeutic options.

Advanced CarcinomaSafety phase (I)Oncology

Post-Stroke Spasticity: Dry Needling vs. Botulinum Toxin

We are exploring how Dry Needling and Botulinum Toxin type A affect spasticity in the lower limbs of stroke survivors. The study will also look at safety, muscle function, and quality of life.

Spasticity after Stroke3-6 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Bladder Cancer: Mitomycin C Treatment Study

We are studying whether a new way to deliver mitomycin C before bladder surgery can lower the risk of cancer returning or worsening in patients with non-muscle invasive bladder tumors.

Non-Muscle Invasive Bladder Tumors>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Tezepelumab for Progressive Pulmonary Fibrosis

We are studying whether Tezepelumab can help reduce symptoms and improve lung function in people with progressive pulmonary fibrosis and high eosinophil levels. This trial compares the medication to a placebo to evaluate its effectiveness.

Interstitial Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePulmonology

Brain Radionecrosis: Bevacizumab vs. Placebo

We are studying whether adding bevacizumab to standard corticosteroid therapy helps improve symptoms and reduce steroid use in patients with brain radionecrosis after radiotherapy. This trial also looks at safety and quality of life.

Brain Metastases and Radionecrosis>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesNeurologyOncology

Neuroendocrine Neoplasms: Metronomic Temozolomide Study

We are investigating the effects of low-dose Temozolomide in patients with advanced neuroendocrine neoplasms who are not fit for traditional treatments. The goal is to see if this approach can improve survival and quality of life.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Advanced Solid Tumors: PAS-004 Treatment Study

We are testing a new drug for patients with advanced solid tumors that have specific genetic mutations. The study aims to assess the safety and how the body handles this treatment in those who have not responded to other therapies.

Malignant Mast Cell Tumors>2 yearsSafety phase (I)Oncology

Pain Relief After Esophageal Procedure: Levobupivacaine Study

We are testing a local anesthetic to see if it helps reduce pain after endoscopic submucosal dissection for esophageal lesions. The study will also look at its safety and impact on recovery time.

Visible Esophageal Lesions (Pre-cancerous)>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Advanced Melanoma: Relatlimab with Nivolumab Study

We are investigating whether combining Relatlimab with Nivolumab helps people with untreated advanced melanoma live longer and have better outcomes than Nivolumab alone.

Metastatic Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Angelman Syndrome: GTX-102 Treatment Study

We are investigating the long-term safety and effectiveness of GTX-102 for individuals with Angelman Syndrome. The study looks at improvements in cognitive function, communication, and motor skills.

Angelman's SyndromeConfirmation phase (III)No PlaceboInvestigational MedicinesNeurology

Hip Replacement: Antibiotic Impregnated Bone Graft Study

We are investigating whether a new antibiotic-infused bone graft can reduce the risk of infection after hip replacement surgery. This study compares it to a standard graft to see which is more effective and safe.

Prosthetic Joint Infection>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInfectious DiseasesOrthopedics and Traumatology